Neisseria gonorrhoeae: Difference between revisions
From IDWiki
Neisseria gonorrhoeae
(→) |
(added link to STI guidelines) |
||
| Line 26: | Line 26: | ||
** MDR gonorrhea: resistance to one of azithromycin or a cephalosporin |
** MDR gonorrhea: resistance to one of azithromycin or a cephalosporin |
||
** XDR if resistance to both azithromycin and a cephalosporin |
** XDR if resistance to both azithromycin and a cephalosporin |
||
== Further Reading == |
|||
* [https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/sexually-transmitted-infections.html#toc Canadian Guidelines on Sexually Transmitted Infections] |
|||
{{DISPLAYTITLE:''Neisseria gonorrhoeae''}} |
{{DISPLAYTITLE:''Neisseria gonorrhoeae''}} |
||
Revision as of 14:47, 31 August 2019
- Causes gonorrhea
Epidemiology
- Resistance
- About 50% resistance to fluoroquinolones
- Rates of MDR gonorrhea is increasing in Canada, mostly driven by azithromycin resistance
- XDR gonorrhea is still rare in Canada 1
Clinical Presentation
Anorectal gonorrhea
- Often asymptomatic
- Can cause anorectal pain, discharge, and pruritis
- Anal intercourse not required, especially in women
Disseminated gonococcal infection
- Classically presents with tenosynovitis (often of wrists) or frank arthritis, with pustular lesions
- Diagnosed with genital testing for gonorrhea, ± blood cultures or arthrocentesis
Diagnosis
- Resistance
- MDR gonorrhea: resistance to one of azithromycin or a cephalosporin
- XDR if resistance to both azithromycin and a cephalosporin
Further Reading
References
- ^ I Martin, P Sawatzky, V Allen, B Lefebvre, LMN Hoang, P Naidu, J Minion, P Van Caeseele, D Haldane, RR Gad, G Zahariadis, A Corriveau, G German, K Tomas, MR Mulvey. Multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae in Canada, 2012–2016. Canada Communicable Disease Report. 2019;45(2/3):45-53. doi:10.14745/ccdr.v45i23a01.
